Mon, Dec 29, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Lipper research highlights difficulties in picking outperforming actively managed funds

Tuesday, May 08, 2012

Beverly Chandler, Opalesque London: A report from Lipper by Ed Moisson, head of UK and Cross-Border Research, examining how successful actively managed mutual funds in Europe have been in out-performing indices over the past twenty years, finds that typically 40% of equity funds out-perform their benchmarks, although this figure varies widely over time and for funds investing in different regions.

In Beating the Benchmark Moisson writes: "Active fund managers’ ability to out-perform their benchmarks sits near the heart of any discussion on the relative merits of active versus passive investing". It is the different level of risk in actively managed funds and the associated additional cost of actively managing investments that weighs against their popularity. Investors are concerned that actively managed funds will, against all that, significantly under-perform the index, Moisson says. "The argument against investing in a passively managed fund is that one not only misses out on the possibility of superior returns that an active manager can offer, but also that, in principle, one is guaranteed to under-perform the index".

However, going by statistics alone, the active fund management industry is clearly more popular with actively managed equity funds in Europe standing at just under €1.5trn, ($1.31trn) while index trackers have €160bn ($209bn) and ETFs €139bn ($181bn). "In other ......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its